Next-generation cell therapy for eligible myeloma and lymphoma patients.
Next-generation cell therapy for eligible myeloma and lymphoma patients.
Autologous, allogeneic, and haploidentical transplants for blood cancers and marrow failure.
Modern drugs that target cancer cells precisely while sparing healthy tissue.